Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) EBT Margin (2016 - 2026)

Ani Pharmaceuticals' EBT Margin history spans 15 years, with the latest figure at 12.74% for Q4 2025.

  • On a quarterly basis, EBT Margin rose 1996.0% to 12.74% in Q4 2025 year-over-year; TTM through Dec 2025 was 10.84%, a 1446.0% increase, with the full-year FY2025 number at 10.84%, up 1446.0% from a year prior.
  • EBT Margin hit 12.74% in Q4 2025 for Ani Pharmaceuticals, down from 14.84% in the prior quarter.
  • Over the last five years, EBT Margin for ANIP hit a ceiling of 18.43% in Q1 2024 and a floor of 50.64% in Q4 2021.
  • Historically, EBT Margin has averaged 7.0% across 5 years, with a median of 0.47% in 2023.
  • Biggest five-year swings in EBT Margin: tumbled -4648bps in 2021 and later soared 4452bps in 2022.
  • Tracing ANIP's EBT Margin over 5 years: stood at 50.64% in 2021, then soared by 88bps to 6.12% in 2022, then surged by 112bps to 0.72% in 2023, then plummeted by -1104bps to 7.22% in 2024, then soared by 276bps to 12.74% in 2025.
  • Business Quant data shows EBT Margin for ANIP at 12.74% in Q4 2025, 14.84% in Q3 2025, and 4.98% in Q2 2025.